Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing cardiac damage in patients treated for breast cancer and lymphoma (PROACT)
2017-001094-16Phase 3Unknown
- Sponsor
- South Tees Hospitals NHS Foundation Trust
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cardiotoxicity and cardiac morbidity comparing Enalapril prophylaxis with Placebo or standard care (2 arms). Primary endpoint: Cardiac troponin T release. Status: unknown.
02
Drugs
enalapril
03
Conditions
Cardiotoxicitycardiac morbidity
Beyond the preview
Go deeper on 2017-001094-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001094-16.